KMT2B and colonic neoplasm: In addition, CBX8 recruits KMT2B (lysine methyltransferases 2B) to the LGR5 promoter, which maintains H3K4me3 status to promote LGR5 expression, resulting in increased cancer stemness and decreased chemosensitivity in colon cancer [40].